AU2010298256B2 - Novel NPR-B agonists - Google Patents

Novel NPR-B agonists Download PDF

Info

Publication number
AU2010298256B2
AU2010298256B2 AU2010298256A AU2010298256A AU2010298256B2 AU 2010298256 B2 AU2010298256 B2 AU 2010298256B2 AU 2010298256 A AU2010298256 A AU 2010298256A AU 2010298256 A AU2010298256 A AU 2010298256A AU 2010298256 B2 AU2010298256 B2 AU 2010298256B2
Authority
AU
Australia
Prior art keywords
leu
arg
asp
occ
phe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010298256A
Other languages
English (en)
Other versions
AU2010298256A1 (en
Inventor
Heiko Hawlisch
Mark R. Hellberg
Gerd Hummel
Tobias Knaute
Frank Osterkamp
Ulf Reimer
Ulrich Reineke
Uwe Richter
Bernadett Simon
Edgar Specker
Markus Woischnik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43781057&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2010298256(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of AU2010298256A1 publication Critical patent/AU2010298256A1/en
Assigned to SHIRE ORPHAN THERAPIES GMBH reassignment SHIRE ORPHAN THERAPIES GMBH Request for Assignment Assignors: ALCON RESEARCH, LTD.
Application granted granted Critical
Publication of AU2010298256B2 publication Critical patent/AU2010298256B2/en
Priority to AU2015255299A priority Critical patent/AU2015255299B2/en
Priority to AU2018202731A priority patent/AU2018202731A1/en
Assigned to TAKEDA PHARMACEUTICAL COMPANY LIMITED reassignment TAKEDA PHARMACEUTICAL COMPANY LIMITED Request for Assignment Assignors: SHIRE ORPHAN THERAPIES GMBH
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2010298256A 2009-09-25 2010-09-23 Novel NPR-B agonists Ceased AU2010298256B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2015255299A AU2015255299B2 (en) 2009-09-25 2015-11-13 Novel npr-b agonists
AU2018202731A AU2018202731A1 (en) 2009-09-25 2018-04-19 Novel npr-b agonists

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24596009P 2009-09-25 2009-09-25
US61/245,960 2009-09-25
PCT/US2010/049912 WO2011038061A2 (en) 2009-09-25 2010-09-23 Novel npr-b agonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2015255299A Division AU2015255299B2 (en) 2009-09-25 2015-11-13 Novel npr-b agonists

Publications (2)

Publication Number Publication Date
AU2010298256A1 AU2010298256A1 (en) 2012-04-12
AU2010298256B2 true AU2010298256B2 (en) 2015-08-13

Family

ID=43781057

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010298256A Ceased AU2010298256B2 (en) 2009-09-25 2010-09-23 Novel NPR-B agonists

Country Status (17)

Country Link
US (5) US8546523B2 (enExample)
EP (1) EP2480247B1 (enExample)
JP (3) JP5893561B2 (enExample)
KR (3) KR101768661B1 (enExample)
CN (2) CN102548574B (enExample)
AR (1) AR078445A1 (enExample)
AU (1) AU2010298256B2 (enExample)
BR (1) BR112012006579A2 (enExample)
CA (1) CA2773949C (enExample)
CL (2) CL2012000715A1 (enExample)
MX (3) MX354005B (enExample)
PH (1) PH12012500562A1 (enExample)
RU (3) RU2557290C2 (enExample)
TW (2) TWI625126B (enExample)
UY (1) UY32902A (enExample)
WO (1) WO2011038061A2 (enExample)
ZA (3) ZA201201630B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2392892T3 (es) 2005-04-07 2012-12-14 Cardiopep Pharma Gmbh Uso de un péptido natriurético para tratar insuficiencia cardiaca
ES2507553T3 (es) * 2006-08-02 2014-10-15 Johannes Gutenberg-Universität Mainz Fármaco contra intoxicaciones por LCT
KR101768661B1 (ko) 2009-09-25 2017-08-16 샤이어 오펀 테라피즈 게엠베하 신규한 ｎｐｒ－ｂ 길항제
TW201121995A (en) 2009-12-18 2011-07-01 Alcon Res Ltd Novel NPR-B agonists
US20150045301A1 (en) * 2011-12-16 2015-02-12 Kalos Therapeutics, Inc. Methods and uses of anp (atrial natriuretic peptide), bnp (brain natriuretic peptide) and cnp (c-type natriuretic peptide)-related peptides and derivatives thereof for treatment of retinal disorders and diseases
EP2948165A2 (en) * 2013-01-25 2015-12-02 Cardiorentis Ltd. A natriuretic peptide, a diuretic peptide or a vasodilatory peptide for use in methods of treating cardiovascular indications
PL3464336T3 (pl) 2016-06-01 2022-05-16 Athira Pharma, Inc. Związki
JP2020505476A (ja) * 2017-02-01 2020-02-20 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 眼科障害の治療のための化合物および組成物
AU2019288296B2 (en) * 2018-06-19 2022-11-24 Cella Therapeutics, Llc Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a CNP compound, an NPR-B compound, a Tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension
AU2019379808C1 (en) * 2018-11-16 2024-01-25 Arcus Biosciences, Inc. Inhibitors of ARG1 and/or ARG2
CA3184145A1 (en) * 2020-06-12 2021-12-16 Pharmain Corporation C-type natriuretic peptides and methods thereof in treating acute lung injury
KR102677730B1 (ko) * 2023-03-27 2024-06-27 나인바이오팜 주식회사 지방 분해 효능을 갖는 펩타이드 및 이의 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080153747A1 (en) * 2004-07-15 2008-06-26 The University Of Queensland Proteinaceous compounds and uses therefor

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757048A (en) 1985-11-05 1988-07-12 Biotechnology Research Associates J.V. Synthetic analogs of atrial natriuretic peptides
AU2927889A (en) * 1987-12-24 1989-07-19 California Biotechnology, Inc. Linear analogs of atrial natriuretic peptides
WO1990001940A1 (en) 1988-08-18 1990-03-08 California Biotechnology Inc. Atrial natriuretic peptide clearance inhibitors
US6833358B1 (en) 1998-09-28 2004-12-21 Santen Pharmaceutical Co., Ltd. Lacrimal secretion promoters or eye drops for treating keratoconjunctival failure containing as the active ingredient natriuretic peptides
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
US6025198A (en) 1999-06-25 2000-02-15 Isis Pharmaceuticals Inc. Antisense modulation of Ship-2 expression
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
IL142118A0 (en) * 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
TWI231759B (en) 2001-06-27 2005-05-01 Alcon Inc Olopatadine formulations for topical administration
US7648962B2 (en) * 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
US7297709B2 (en) 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
TW200640443A (en) 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
US20090035287A1 (en) * 2005-09-26 2009-02-05 Zurit Levine Atrial natriuretic peptide (anp) splice variants and methods of using same
CA2625600A1 (en) * 2005-10-14 2007-04-26 Biorexis Pharmaceutical Corporation Natriuretic peptide modified transferrin fusion proteins
AU2007233123A1 (en) * 2006-03-30 2007-10-11 Palatin Technologies, Inc. Linear natriuretic peptide constructs
BRPI0709427A2 (pt) 2006-03-30 2011-07-12 Palatin Technologies Inc "construto cìclico, composição farmacêutica e uso de um composto
AR069409A1 (es) * 2007-11-21 2010-01-20 Biomarin Pharm Inc Variantes de peptidos natriureticos de tipo c
KR101768661B1 (ko) * 2009-09-25 2017-08-16 샤이어 오펀 테라피즈 게엠베하 신규한 ｎｐｒ－ｂ 길항제
WO2011038066A2 (en) 2009-09-25 2011-03-31 Alcon Research, Ltd. Novel npr-b agonists
TW201121995A (en) 2009-12-18 2011-07-01 Alcon Res Ltd Novel NPR-B agonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080153747A1 (en) * 2004-07-15 2008-06-26 The University Of Queensland Proteinaceous compounds and uses therefor

Also Published As

Publication number Publication date
ZA201702958B (en) 2018-08-29
KR20170094564A (ko) 2017-08-18
TWI625126B (zh) 2018-06-01
US9982016B2 (en) 2018-05-29
US20130345394A1 (en) 2013-12-26
PH12012500562A1 (en) 2012-10-22
US20180334477A1 (en) 2018-11-22
AU2010298256A1 (en) 2012-04-12
TWI577384B (zh) 2017-04-11
MX2012003398A (es) 2012-04-10
RU2636738C2 (ru) 2017-11-28
CN105732767A (zh) 2016-07-06
US20160194357A1 (en) 2016-07-07
CA2773949A1 (en) 2011-03-31
KR101854820B1 (ko) 2018-05-04
EP2480247B1 (en) 2020-02-12
RU2557290C2 (ru) 2015-07-20
JP2017137362A (ja) 2017-08-10
MX370645B (es) 2019-12-19
US8546523B2 (en) 2013-10-01
WO2011038061A2 (en) 2011-03-31
KR20120091110A (ko) 2012-08-17
KR20180049198A (ko) 2018-05-10
AR078445A1 (es) 2011-11-09
JP5893561B2 (ja) 2016-03-23
US9169293B2 (en) 2015-10-27
CL2012000715A1 (es) 2012-11-30
US20170313743A1 (en) 2017-11-02
TW201630619A (zh) 2016-09-01
ZA201201630B (en) 2014-05-28
US20110077381A1 (en) 2011-03-31
UY32902A (es) 2011-02-28
RU2015124607A (ru) 2015-12-10
EP2480247A2 (en) 2012-08-01
JP6211032B2 (ja) 2017-10-11
CA2773949C (en) 2020-11-03
US9745344B2 (en) 2017-08-29
CN102548574A (zh) 2012-07-04
ZA201401625B (en) 2018-08-25
EP2480247A4 (en) 2013-09-04
US10196423B2 (en) 2019-02-05
TW201110974A (en) 2011-04-01
MX354005B (es) 2018-02-08
BR112012006579A2 (pt) 2016-11-22
RU2017139870A3 (enExample) 2019-05-16
WO2011038061A3 (en) 2011-07-28
RU2017139870A (ru) 2019-05-16
RU2012116531A (ru) 2013-10-27
CL2017001190A1 (es) 2017-12-01
JP2015131856A (ja) 2015-07-23
CN102548574B (zh) 2016-03-23
KR101768661B1 (ko) 2017-08-16
JP2013505937A (ja) 2013-02-21

Similar Documents

Publication Publication Date Title
AU2010298256B2 (en) Novel NPR-B agonists
US8551938B2 (en) NPR-B agonists
WO2011075471A2 (en) Novel npr-b agonists and methods of use for the treatment of c-type natriuretic peptide-mediated disorders
US20180094029A1 (en) Methods of treating ophthalmic diseases using npr-b agonists
US9458198B1 (en) Cyclic peptide-based NPR-B agonists
AU2015255299B2 (en) Novel npr-b agonists
HK1173070A (en) Novel npr-b agonists
HK1173070B (en) Novel npr-b agonists
HK1226800A1 (en) Novel npr-b agonists
HK1226800A (en) Novel npr-b agonists

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: SHIRE ORPHAN THERAPIES GMBH

Free format text: FORMER APPLICANT(S): ALCON RESEARCH, LTD.

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Free format text: FORMER OWNER(S): SHIRE ORPHAN THERAPIES GMBH

MK14 Patent ceased section 143(a) (annual fees not paid) or expired